Eiji Iwama

2.8k total citations · 2 hit papers
70 papers, 1.9k citations indexed

About

Eiji Iwama is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Eiji Iwama has authored 70 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Pulmonary and Respiratory Medicine, 42 papers in Oncology and 16 papers in Molecular Biology. Recurrent topics in Eiji Iwama's work include Lung Cancer Treatments and Mutations (46 papers), Lung Cancer Research Studies (17 papers) and Cancer Immunotherapy and Biomarkers (14 papers). Eiji Iwama is often cited by papers focused on Lung Cancer Treatments and Mutations (46 papers), Lung Cancer Research Studies (17 papers) and Cancer Immunotherapy and Biomarkers (14 papers). Eiji Iwama collaborates with scholars based in Japan, United States and China. Eiji Iwama's co-authors include Yoichi Nakanishi, Isamu Okamoto, Keiichi Ota, Koichi Takayama, Koichi Azuma, Taishi Harada, Koichiro Matsumoto, Tomoaki Hoshino, Satoshi Hattori and Shinzo Takamori and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Scientific Reports.

In The Last Decade

Eiji Iwama

66 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer

2014 525 citations Koichi Azuma, Keiichi Ota et al. profile →
Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer

2015 366 citations Keiichi Ota, Koichi Azuma et al. Clinical Cancer Research profile →

Peers

Countries citing papers authored by Eiji Iwama

Since Specialization

Citations

This map shows the geographic impact of Eiji Iwama's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eiji Iwama with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eiji Iwama more than expected).

Fields of papers citing papers by Eiji Iwama

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eiji Iwama. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eiji Iwama. The network helps show where Eiji Iwama may publish in the future.

Co-authorship network of co-authors of Eiji Iwama

This figure shows the co-authorship network connecting the top 25 collaborators of Eiji Iwama. A scholar is included among the top collaborators of Eiji Iwama based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eiji Iwama. Eiji Iwama is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring EGFR Mutation 2025 ·Clinical Cancer Research ·Shintaro Kanda, Seiji Niho, Takayasu Kurata, Shogo Nomura, Yosuke Kawashima, Eiji Iwama, Toshihide Yokoyama, Yasutaka Watanabe, Hiroshi Tanaka, Yutaka Fujiwara, Yoshitaka Zenke, Koichi Azuma, Hirokazu Taniguchi, Ryo Toyozawa, Yukio Hosomi, Haruyasu Murakami, (unknown), Akihiro Bessho, Nobuyuki Yamamoto, Yuichiro Ohe	1
2	Suitability of Frozen Pleural Fluid Pellets for Next‐Generation Sequencing‐Based Driver Gene Testing in Non‐Small Cell Lung Cancer 2025 ·Thoracic Cancer ·Kazuki Nakashima, Kohei Otsubo, (unknown), (unknown), Eiji Iwama, Eiji Harada, (unknown)	0
3	Remarkable response to crizotinib in a patient with advanced lung adenocarcinoma harboring the MPRIP-ROS1 fusion gene: A case report 2025 ·Respiratory Medicine Case Reports ·(unknown), Kohei Otsubo, (unknown), Yoshimasa Shiraishi, (unknown), Eiji Iwama, (unknown)	0
4	TP53 gain-of-function mutations promote osimertinib resistance via TNF-α–NF-κB signaling in EGFR-mutated lung cancer 2024 ·npj Precision Oncology ·(unknown), Eiji Iwama, (unknown), (unknown), Yasuto Yoneshima, Kentaro Tanaka, Isamu Okamoto	13
5	Tracheomediastinal fistula induced by concurrent chemoradiotherapy in small cell lung cancer: A case report and literature review 2024 ·Thoracic Cancer ·Yoshihiro Yamamoto, (unknown), (unknown), Kohei Otsubo, Yoshimasa Shiraishi, Yasuto Yoneshima, Eiji Iwama, Kentaro Tanaka, Yoshinao Oda, Isamu Okamoto	1
6	MicroRNA‐326 negatively regulates CD155 expression in lung adenocarcinoma 2023 ·Cancer Science ·(unknown), Yasuto Yoneshima, Koji Okamura, Toyoshi Yanagihara, Mikiko Hashisako, Takeshi Iwasaki, Naoki Haratake, (unknown), Keiichi Ota, Eiji Iwama, Tomoyoshi Takenaka, Kentaro Tanaka, Tomoharu Yoshizumi, Yoshinao Oda, Isamu Okamoto	4
7	Impact of increased plasma levels of calreticulin on prognosis of patients with advanced lung cancer undergoing combination treatment of chemotherapy and immune checkpoint inhibitors 2023 ·Lung Cancer ·(unknown), Hiroyuki Inoue, Yoshimasa Shiraishi, (unknown), (unknown), Hiroyuki Ando, (unknown), (unknown), Hiroaki Ogata, Koji Okamura, Shinichi Kimura, Tomohiro Ogawa, Keiichi Ota, Yasuto Yoneshima, Kentaro Tanaka, Naoki Hamada, Isamu Okamoto, Eiji Iwama	8
8	Evaluation of appropriate conditions for Oncomine DxTT testing of FFPE specimens for driver gene alterations in non–small cell lung cancer 2023 ·Thoracic Cancer ·Eiji Iwama, Hidetaka Yamamoto, (unknown), Kayo Ijichi, (unknown), (unknown), Yasuto Yoneshima, Kentaro Tanaka, Yoshinao Oda, Isamu Okamoto	4
9	YAP mediates resistance to EGF-induced apoptosis in EGFR-mutated non-small cell lung cancer cells 2023 ·Biochemical and Biophysical Research Communications ·(unknown), Kentaro Tanaka, Yasuto Yoneshima, (unknown), (unknown), Eiji Iwama, Isamu Okamoto	0
10	Immunostimulatory oncolytic activity of coxsackievirus A11 in human malignant pleural mesothelioma 2022 ·Cancer Science ·Koji Okamura, Hiroyuki Inoue, Kentaro Tanaka, (unknown), (unknown), Keiichi Ota, Yasuto Yoneshima, Eiji Iwama, Isamu Okamoto	5
11	Mutant forms of EGFR promote HER2 trafficking through efficient formation of HER2-EGFR heterodimers 2022 ·Lung Cancer ·(unknown), Eiji Iwama, (unknown), (unknown), Keiichi Ota, (unknown), Hiroyuki Inoue, Kentaro Tanaka, Yoichi Nakanishi, Isamu Okamoto	5
12	Quantification of HER family dimers by proximity ligation assay and its clinical evaluation in non–small cell lung cancer patients treated with osimertinib 2021 ·Lung Cancer ·Renpeng Liu, Keiichi Ota, Eiji Iwama, (unknown), Kentaro Tanaka, Hiroyuki Inoue, Tetsuzo Tagawa, Yoshinao Oda, Masaki Mori, Yoichi Nakanishi, (unknown)	4
13	NEUROD1 is highly expressed in extensive-disease small cell lung cancer and promotes tumor cell migration 2020 ·Lung Cancer ·(unknown), Kentaro Tanaka, Gouji Toyokawa, Kayo Ijichi, (unknown), Yasuto Yoneshima, Eiji Iwama, Hiroyuki Inoue, Tetsuzo Tagawa, Yoichi Nakanishi, Isamu Okamoto	22
14	Chronic myelomonocytic leukemia blast crisis in a patient with advanced non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors 2017 ·Respiratory Investigation ·Hiroaki Ogata, Isamu Okamoto, Goichi Yoshimoto, (unknown), Kayo Ijichi, Eiji Iwama, Taishi Harada, Koichi Akashi, Yoichi Nakanishi	2
15	CD44 variant–dependent regulation of redox balance in EGFR mutation–positive non–small cell lung cancer: A target for treatment 2017 ·Lung Cancer ·Yuko Kawano, Eiji Iwama, Kenji Tsuchihashi, (unknown), Taishi Harada, Kentaro Tanaka, Osamu Nagano, Hideyuki Saya, Yoichi Nakanishi, Isamu Okamoto	10
16	Characteristics of Smoking Patients with Lung Cancer with Emphysematous Bullae 2016 ·Journal of Thoracic Oncology ·Eiji Iwama, Isamu Okamoto, Hidetake Yabuuchi, Koichi Takayama, Taishi Harada, Yoshio Matsuo, Shoji Tokunaga, Eishi Baba, Yoichi Nakanishi	11
17	Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer breakdown → 2015 ·Clinical Cancer Research ·Keiichi Ota, Koichi Azuma, Akihiko Kawahara, Satoshi Hattori, Eiji Iwama, Junko Tanizaki, Taishi Harada, Koichiro Matsumoto, Koichi Takayama, Shinzo Takamori, Masayoshi Kage, Tomoaki Hoshino, Yoichi Nakanishi, Isamu Okamoto	366
18	Nicotine induces resistance to erlotinib via cross-talk between α 1 nAChR and EGFR in the non-small cell lung cancer xenograft model 2015 ·Lung Cancer ·Heyan Li, Shuo Wang, Koichi Takayama, Taishi Harada, Isamu Okamoto, Eiji Iwama, Akiko Fujii, Keiichi Ota, Noriko Hidaka, Yuko Kawano, Yoichi Nakanishi	32
19	Infected complex renal cysts during crizotinib therapy in a patient with non–small cell lung cancer positive for ALK rearrangement 2014 ·Investigational New Drugs ·Yasuto Yoneshima, Isamu Okamoto, (unknown), Shinichi Kimura, (unknown), Eiji Iwama, Taishi Harada, Koichi Takayama, Yoichi Nakanishi	9
20	Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR‐tyrosine kinase inhibitors 2013 ·Cancer Science ·Kazuto Furuyama, Taishi Harada, Eiji Iwama, Yoshimasa Shiraishi, Kyoko Okamura, Kayo Ijichi, Akiko Fujii, Keiichi Ota, Shuo Wang, Heyan Li, Koichi Takayama, Giuseppe Giaccone, Yoichi Nakanishi	43

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact